Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. - Wikidata - wikimedia - TriplyDB

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q38098483

about

Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Golimumab: A Review in Inflammatory Arthritis.Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

P2860

Q34573847-DFC98D48-5498-4DFA-88D0-F7755026C9E3 Q36844535-702090A9-616C-4011-B456-2E2B2DDF47AD Q38097338-1AD46FD0-42B2-4CAE-9B43-C7B0C045318D Q38098484-805AB734-1720-41CF-8B3A-8697B2DA22DB Q38133381-39DD7971-39E2-4842-9504-9A35D8B8DD32 Q38149091-57CC9016-6204-471E-A51B-A42A8ED92130 Q38771878-2B6A2016-54A0-4FC7-BE2A-12CC5229F829 Q45893661-FA1DFD65-4A01-48C8-B914-40E1FA4A255C

P2860

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q38098483

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Golimumab for the treatment of ...... E single technology appraisal.

@en

type

label

Golimumab for the treatment of ...... E single technology appraisal.

@en

prefLabel

Golimumab for the treatment of ...... E single technology appraisal.

@en

P1433

Q38098483-83A029F5-5FCE-4E2B-A82E-02A2F150401C

P1476

Q38098483-C201D545-E82C-4E07-9193-265372BABC37

P2093

Q38098483-15EDAAA2-6F9E-4C96-83CC-2B39034C9C69

Q38098483-A3ABE3F4-F0E0-4FD5-B909-94484C357A85

Q38098483-A595E5BE-4F9E-452E-89FC-4BFE7F9ABC2C

Q38098483-A6F38E8C-DA9B-4433-BFB0-678964B7A170

Q38098483-A96F3649-9AA6-4AB5-AD78-E54D67E84066

Q38098483-D5E61446-457E-46E1-91C9-A417C9D951B1

Q38098483-E5B08C6B-DA52-4A1E-B48B-7332057F54F2

Q38098483-F99B6061-C39F-4BC7-BAA6-DD347F9D971A

P2860

Q38098483-029E6FA6-F6EF-45E4-8FEB-14CA79CB2B3A

Q38098483-0AD2C7C1-D3F8-477A-876A-AD1DAE458141

Q38098483-0EA140AD-CC62-46A0-BBF0-2599F1FE8FCF

Q38098483-1131C06D-886C-47EA-BEF0-563B0EA966B2

Q38098483-223C9D0F-4187-4BFB-9492-5AD48041F1B7

Q38098483-2B8F886D-6A00-4784-ADF8-7C2004534BB4

Q38098483-31981110-BE1D-4DC0-8AEE-2BE134441F2F

Q38098483-351EEAB1-FCFE-49D6-98BA-020A3FB2E701

Q38098483-358ED8EF-1448-4A54-ADC4-0FC6C0C6BE8C

Q38098483-35A11797-1E9E-4B46-879B-DF3186B77F30

P2888

Q38098483-DB67DEC4-DFAC-4DC0-BA0A-76BE806ED389

P304

Q38098483-224DFB5C-9024-4E5F-8107-177741EE6E89

P31

Q38098483-508A58AB-D128-4936-B02B-AE42A87DB54D

P356

Q38098483-0C537C12-1FE0-44F9-8C67-F2FC41550C74

P433

Q38098483-FB9F2318-B662-4D5C-85CA-A06751F12402

P478

Q38098483-CE07CE31-1EF3-4BB0-B648-4BE642F3A01A

P577

Q38098483-2646893F-AA55-48B3-B183-909935CB8926

P698

Q38098483-3EF998D9-3E2A-4659-933E-DEB145EF3E4D

P356

S40273-013-0049-2

P1433

PharmacoEconomics

P1476

Golimumab for the treatment of ...... E single technology appraisal.

@en

P2093

Florian Tomini

http://www.w3.org/2001/XMLSchema#string

Jos Kleijnen

http://www.w3.org/2001/XMLSchema#string

Kate Misso

http://www.w3.org/2001/XMLSchema#string

Manuela Joore

http://www.w3.org/2001/XMLSchema#string

Nathan Manning

http://www.w3.org/2001/XMLSchema#string

Nigel Armstrong

http://www.w3.org/2001/XMLSchema#string

Rob Riemsma

http://www.w3.org/2001/XMLSchema#string

Thea van Asselt

http://www.w3.org/2001/XMLSchema#string

P2860

Physiotherapy interventions for ankylosing spondylitis

Methotrexate for ankylosing spondylitis

Sulfasalazine for ankylosing spondylitis

Ankylosing spondylitis: an overview

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.

ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.

How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?

P2888

s40273-013-0049-2

P304

415-425

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-013-0049-2

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23580355

http://www.w3.org/2001/XMLSchema#string